Table 5.
Failure pattern and dosimetric characteristics in patients with nodal recurrence
| Patient nº | Localization nodal failure | XRT volume | Failure (month) | Volume (cc) | Minimum dose (cGy) | Maximum dose (cGy) | Mean dose (cGy) |
|---|---|---|---|---|---|---|---|
| 1 |
II-III ipsilateral |
Nodal CTV2 |
6 |
9.1 |
6498.2 |
6980.0 |
6602.9 |
| 2 |
III-IV ipsilateral |
Nodal CTV2 |
12 |
3.45 |
6489.9 |
6995.9 |
6629.5 |
| 3 |
II ipsilateral |
Nodal CTV1 |
14 |
2.8 |
4399.0 |
6551.2 |
5554.1 |
| |
|
(Nodal CTV2 marginal) |
|
|
|
|
|
| 4 |
III ipsilateral |
Nodal CTV0 |
9 |
9.35 |
175.1 |
3113.2 |
1191.4 |
| 5 |
III ipsilateral |
Nodal CTV1 |
8 |
1.83 |
5685.5 |
7005.2 |
6535.1 |
| II ipsilateral |
Nodal CTV2 |
8 |
2.51 |
6652.8 |
6741.6 |
6701.8 |
|
| 6 |
II ipsilateral |
Nodal CTV2 |
7 |
3.5 |
7009.1 |
7255.1 |
7149.8 |
| 7 |
V ipsilateral |
Nodal CTV0 |
19 |
3.1 |
195.0 |
5050.1 |
2789.8 |
| 8 |
Ib-II ipsilateral |
Nodal CTV2 |
8 |
3.35 |
6561.1 |
7171.2 |
6805.5 |
| 9 |
II-III ipsilateral |
Nodal CTV0 |
17 |
2.9 |
589.9 |
5101.0 |
3091.0 |
| |
|
(nodal CTV1 marginal) |
|
|
|
|
|
| 10 |
Ib ipsilateral |
Nodal CTV1 |
11 |
2.8 |
6491.0 |
7001.0 |
6682.2 |
| II ipsilateral |
Nodal CTV2 |
11 |
1.9 |
4901.0 |
6281.2 |
5402.3 |
|
| 11 |
II ipsilateral |
Nodal CTV2 |
7 |
9.8 |
6595.3 |
6798.4 |
6639.0 |
| 12 |
Ib ipsilateral |
Nodal CTV2 |
7 |
2.9 |
6598.2 |
6792.0 |
6689.3 |
| 13 |
II ipsilateral |
Nodal CTV2 |
8 |
2.1 |
6601.4 |
6850.1 |
6602.2 |
| 14 |
Ib ipsilateral |
Nodal CTV2 |
11 |
2.8 |
6599.0 |
6899.4 |
6598.0 |
| 15 | Ib ipsilateral | Nodal CTV2 | 10 | 10.2 | 6278.7 | 7195.5 | 6658.9 |
Abbreviations: CTV0 = low-risk clinical target volume; CTV1 = moderate-risk clinical target volume;
CTV2 = high-risk clinical target volume.